Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE: EBS) announced a supply partnership with the B.C. Provincial Health Services Authority to provide NARCAN® Nasal Spray as British Columbia expands its Take-Home Naloxone Program following an $18 million CAD provincial investment.
The rollout expands a 2024 pilot that delivered 60,000 nasal kits; Emergent reports delivering >100 million NARCAN doses in Canada and the U.S. since 2016 and employs over 300 people in Canada.
Emergent BioSolutions (NYSE: EBS) on April 7, 2026 launched a new NARCAN® Nasal Spray Carrying Case, expanded 6-count and 24-count multipacks, and began a college outreach effort titled Ready to Rescue featuring Emmitt Smith and Zac Clark.
The initiatives aim to increase naloxone access, address low carry rates, and support campus preparedness; carrying case is available on Amazon and multipacks on NarcanDirect.com.
Emergent BioSolutions (NYSE: EBS) said members of its products, medical affairs, government and public affairs teams will participate in four international preparedness conferences in April–June 2026.
Conferences listed include London Defence Conference (April 10–11), CBRN Research & Innovation (May 19–21), Global Health Security (June 9–12) and BIO International Convention (June 20–22). The company emphasized collaboration with governments on medical countermeasures for threats such as smallpox, anthrax, botulism and Ebola.
Emergent BioSolutions (NYSE: EBS) announced a U.S. government contract option exercise of approximately $54 million to deliver CNJ-016 (VIGIV) to ASPR for smallpox preparedness, plus $6.6 million in new international orders for ACAM2000. The release cites prior multi-year Canada agreements up to $140 million CAD with >$35 million CAD expected in 2026.
The orders cover licensed medical countermeasures and include U.S. FDA-approved indications and safety warnings for VIGIV and ACAM2000.
Emergent BioSolutions (NYSE: EBS) appointed John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler will serve on the Audit and Finance Committee and brings over three decades of senior leadership in healthcare and financial services.
His background includes senior roles at Wells Fargo Securities, Deutsche Bank, JPMorgan, and previous biotech executive and board experience. Mr. Fowler holds a JD, an MBA from Darden, and a BA in History from the University of Virginia.
Emergent BioSolutions (NYSE: EBS) reported Q4 2025 total revenue of $148.7M and FY2025 total revenue of $742.9M. Q4 net loss was $54.6M, while FY2025 net income was $52.6M and adjusted EBITDA was $205.0M. Gross margin expanded to 45% and adjusted gross margin to 54%. Company repurchased $24.8M of stock in 2025, authorized an additional $50M plan, and made a voluntary $100M term loan principal payment. Key 2025 contract awards and naloxone revenue (> $226M) were highlighted.
Emergent BioSolutions (NYSE: EBS) announced a new $50 million stock repurchase program authorized by the Board, effective through March 31, 2027, replacing a prior authorization that expired March 27, 2026.
The prior program allowed up to $50 million; the company repurchased $24.8 million under that plan. Repurchases may occur on the open market or in privately negotiated transactions and may be suspended at any time. The company had approximately 52 million shares outstanding as of February 19, 2026.
Emergent BioSolutions (NYSE: EBS) announced multiyear contracts and a contract modification with the Public Health Agency of Canada and Department of National Defence valued at up to approximately CAD 140 million. Emergent expects more than CAD 35 million in orders in 2026 and will supply four medical countermeasures, several made at its Health Canada–licensed facility to strengthen domestic production and surge capacity.
Committed annual procurements aim to ensure continuous production, rapid conversion to finished product, and long-term strategic stockpiling to support Canada's biodefence readiness.
Emergent BioSolutions (NYSE: EBS) announced FDA approval of an sNDA on Feb 12, 2026, for OTC NARCAN® Nasal Spray multipacks in new 6-count and 24-count configurations.
The multipacks are designed for higher-volume distribution, will be sold to public interest customers via NARCANDirect, and complement a January 2026 FDA approval of the NARCAN carrying case. Existing product formats will remain available. Since 2016, more than 85 million doses have been distributed in the U.S. and Canada.
Emergent BioSolutions (NYSE: EBS) will report fourth quarter and full year 2025 financial results and host a conference call on Thursday, February 26, 2026 at 5:00 PM ET.
Investors can join via live webcast on the company’s Investors page or by telephone after registering in advance; a replay will be posted on the Investors page.